Monocyte or white blood cell counts and β(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide.

Shimazu Y, Kanda J, Kaneko H, Imada K, Yamamura R, Kosugi S, Shimura Y, Ito T, Fuchida SI, Uchiyama H, Fukushima K, Yoshihara S, Hanamoto H, Tanaka H, Uoshima N, Ohta K, Yagi H, Shibayama H, Onda Y, Tanaka Y, Adachi Y, Matsuda M, Iida M, Miyoshi T, Matsui T, Takahashi R, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J, Kansai Myeloma Forum

Open source

DOI: 10.1177/20406207221142487
Published: 2022
Container: Therapeutic advances in hematology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/20406207221142487,
  title = {Monocyte or white blood cell counts and β(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide.},
  author = {Shimazu Y and Kanda J and Kaneko H and Imada K and Yamamura R and Kosugi S and Shimura Y and Ito T and Fuchida SI and Uchiyama H and Fukushima K and Yoshihara S and Hanamoto H and Tanaka H and Uoshima N and Ohta K and Yagi H and Shibayama H and Onda Y and Tanaka Y and Adachi Y and Matsuda M and Iida M and Miyoshi T and Matsui T and Takahashi R and Takakuwa T and Hino M and Hosen N and Nomura S and Shimazaki C and Matsumura I and Takaori-Kondo A and Kuroda J and Kansai Myeloma Forum},
  year = {2022},
  journal = {Therapeutic advances in hematology},
  doi = {10.1177/20406207221142487},
  url = {https://doi.org/10.1177/20406207221142487}
}

RIS

TY  - JOUR
TI  - Monocyte or white blood cell counts and β(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide.
AU  - Shimazu Y
AU  - Kanda J
AU  - Kaneko H
AU  - Imada K
AU  - Yamamura R
AU  - Kosugi S
AU  - Shimura Y
AU  - Ito T
AU  - Fuchida SI
AU  - Uchiyama H
AU  - Fukushima K
AU  - Yoshihara S
AU  - Hanamoto H
AU  - Tanaka H
AU  - Uoshima N
AU  - Ohta K
AU  - Yagi H
AU  - Shibayama H
AU  - Onda Y
AU  - Tanaka Y
AU  - Adachi Y
AU  - Matsuda M
AU  - Iida M
AU  - Miyoshi T
AU  - Matsui T
AU  - Takahashi R
AU  - Takakuwa T
AU  - Hino M
AU  - Hosen N
AU  - Nomura S
AU  - Shimazaki C
AU  - Matsumura I
AU  - Takaori-Kondo A
AU  - Kuroda J
AU  - Kansai Myeloma Forum
PY  - 2022
JO  - Therapeutic advances in hematology
DO  - 10.1177/20406207221142487
UR  - https://doi.org/10.1177/20406207221142487
ER  -

APA

Y, S., J, K., H, K., K, I., R, Y., S, K., Y, S., T, I., SI, F., H, U., K, F., S, Y., H, H., H, T., N, U., K, O., H, Y., H, S., Y, O., Y, T., Y, A., M, M., M, I., T, M., T, M., R, T., T, T., M, H., N, H., S, N., C, S., I, M., A, T., J, K., & Forum, K. M. (2022). Monocyte or white blood cell counts and β(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide.. Therapeutic advances in hematology. https://doi.org/10.1177/20406207221142487

Source records

pubmed · retrieved 2026-09-27T01:13:04.850Z
europe-pmc · retrieved 2026-09-27T01:13:04.866Z
doaj · retrieved 2026-09-27T01:13:04.871Z